PASIREOTIDE CAS 396091-73-9

Deskripsyon pwodwi:

Non pwodwi: PASIREOTIDE CAS NON: 396091-73-9

Sinonim:

Cyclo [(2S) -2-phenylglycyl-D-tryptophyl-L-lysyl-O- (phenylmethyl) -L-tyrosyl-L-phenylalanyl- (4R) -4 - [[[(2-aminoethyl) amino] carbonyl] oksi] -L-prolil];

[(3S, 6S, 9S, 12R, 15S, 18S, 20R) -9- (4-aminobutil) -3-benzil-12- (1H-indol-3-ilmetil) -2,5,8,11,14 , 17-hexaoxo-15-phenyl-6 - [(4-phenylmethoxyphenyl) methyl] -1,4,7,10,13,16-hexazabicyclo [16.3.0] henicosan-20-il] N- (2-aminoethyl ) karbamat;

Chimik& Pwopriyete fizik:

Aparans: kristalin solid

Egzamen: ≥99.00%

Dansite: 1.4 ± 0.1 g / cm3

Pwen bouyi: 1351.4 ± 65.0 ℃ nan 760 mmHg

Flash Point: 771.1 ± 34.3 ℃

Presyon vapè: 0.0 ± 0.3 mmHg nan 25 ℃

Endèks Refraksyon: 1.680

Pasireotide (SOM230, non komèsyal Signifor) se yon dwòg òfelen apwouve nan peyi Etazini ak Ewòp pou tretman maladi Cushing' ak akromegaly nan pasyan ki echwe oswa ki pa kalifye pou terapi chirijikal. Li te devlope pa Novartis. Pasireotide se yon analòg somatostatin ak yon 40-pliye ogmante afinite nan reseptè somatostatin 5 konpare ak lòt analòg somatostatin.

Pasireotide te apwouve pou maladi Cushing&# 39 a pa EMEA nan mwa Oktòb 2009 ak pa FDA nan Desanm 2012. Pasireotide LAR te apwouve pa FDA pou tretman acromégalie nan Desanm 2014, e te apwouve pou endikasyon sa a pa EMEA a yon mwa pi bonè.

Si ou enterese nan pwodwi nou yo oswa ou gen nenpòt kesyon, tanpri ou lib pou kontakte nou!

Pwodwi anba patant yo ofri pou R& D objektif sèlman. Sepandan, responsablite final la manti sèlman ak achtè a.

Baj popilè: pasireotide CAS 396091-73-9, manifaktirè, founisè, faktori, achte, nan stock

• On: BNP-32 (imen) CAS 124584-08-3
• Pwochen: Octreotide CAS 79517-01-4